Clinical trials: Pseudomonas Aeruginosa
CARRIER STATE
Efficacy of a Probiotic or Fecal Microbiota Transplantation (FMT) on the Eradication of Rectal Multidrug-resistant Gram-negative Bacilli (MDR-GNB) Carriage (PROFTMDECOL)
The working hypothesis is that in patients who are rectal carriers of MDR-GNB (Multi drug-resistant gram negative bacilli), the rate and speed of eradication of the carrier status obtained with NAA regimens are insufficient and…
- Trial name
- PROFTMDECOL (NCT04431934)
- Testing
- PROBIOTIC, FMT REGIMEN
- Where
- Spain
- Volunteers
- 437 people
- Sponsor
- Hospital Clinic of Barcelona
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Pseudomonas Infections, Pseudomonas Aeruginosa
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
- Trial name
- NCT03510351
- Testing
- Ceftolozane-Tazobactam
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Temple University
Cystic Fibrosis
Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive…
- Trial name
- ROSCO-CF (NCT02649751)
- Testing
- Roscovitine
- Where
- 11 sites in France
- Volunteers
- 49 people
- Sponsor
- University Hospital, Brest
Pseudomonas Aeruginosa, Multi-antibiotic Resistance
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.
- Trial name
- ABAC-IBS (NCT04335383)
- Testing
- Isolation of anti-Pseudomonas antibodies from type B lymphocytes
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Cystic Fibrosis
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P.
- Trial name
- NCT00777296
- Testing
- ARIKACE™
- Where
- 11 sites in Belgium, Hungary and 5 more
- Volunteers
- 66 people
- Sponsor
- Insmed Incorporated
Cystic Fibrosis
Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life
The goal of this study is characterize the changes in bacterial diversity of the upper respiratory tracts of infants with cystic fibrosis (CF).
- Trial name
- NCT00977158
- Testing
- Throat Swab
- Where
- 2 sites in United States
- Sponsor
- Tufts Medical Center
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Bacteremia
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.
- Trial name
- DIREBT (NCT01919762)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- T2 Biosystems
Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of…
- Trial name
- OPTIMIZE (NCT02054156)
- Testing
- azithromycin, Tobramycin solution for inhalation
- Where
- 45 sites in United States
- Volunteers
- 221 people
- Sponsor
- Bonnie Ramsey
Cystic Fibrosis, Infection
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- PseudIgY (NCT00633191)
- Testing
- Anti-pseudomonas IgY gargle
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Immunsystem AB
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Cystic Fibrosis
Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa
This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in patients with Cystic Fibrosis who have a…
- Trial name
- NCT01090908
- Testing
- Antibiotic
- Sponsor
- Aradigm Corporation
Cystic Fibrosis
Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy
The purpose of this study is to determine whether choosing antibiotics based on a biofilm antimicrobial susceptibility assay rather than a conventional planktonic antimicrobial susceptibility assay to treat CF patients with…
- Trial name
- NCT00786513
- Testing
- Conventional antimicrobial susceptibility testing, Biofilm antimicrobial susceptibility testing
- Where
- 5 sites in Canada
- Volunteers
- 134 people
- Sponsor
- The Hospital for Sick Children
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Bronchiectasis
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis.
- Trial name
- ANTEIPA (NCT06368804)
- Testing
- Antibiotic monotherapy treatment and follow-up, Antibiotic bitherapy treatment and follow-up
- Where
- 18 sites in France
- Volunteers
- 196 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Tracheostomy Infection
The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas
This is a prospective, case-control clinical trial using inhaled Aztreonam (AZLI) in pediatric patients with a tracheostomy tube colonized with Pseudomonas aeruginosa.
- Trial name
- A-PACT (NCT03158116)
- Testing
- Inhaled Aztreonam
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Cystic Fibrosis
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa.
- Trial name
- NCT04684641
- Testing
- Standard Dose YPT-01
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Postoperative Seroma Rate, Drainage Tube Removal Time, and Capsular Contracture Rate, Seroma Following Procedure
Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants
Brief Summary This study hypothesizes that in immediate breast reconstruction following tumor resection, the application of inactivated Pseudomonas aeruginosa preparation (PAP) may reduce infection rates by decreasing…
- Trial name
- RCT of PAI + P (NCT07460297)
- Testing
- Pseudomonas aeruginosa, Povidone-Iodine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jianyi Li
Pseudomonas Aeruginosa
Pathobiomes in Gut of Critically Ill Patients
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain…
- Trial name
- NCT06822465
- Testing
- P. aeruginosa using in vitro and in vivo assays
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Chicago